Mitigating alemtuzumab-associated autoimmunity in MS: A “whack-a-mole” B-cell depletion strategy

OBJECTIVE: To determine whether the punctuated administration of low-dose rituximab, temporally linked to B-cell hyperrepopulation (defined when the return of CD19(+) B cells approximates 40%–50% of baseline levels as measured before alemtuzumab treatment inception), can mitigate alemtuzumab-associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Meltzer, Ethan, Campbell, Sarah, Ehrenfeld, Benjamin, Cruz, Roberto A., Steinman, Lawrence, Parsons, Matthew S., Zamvil, Scott S., Frohman, Elliot M., Frohman, Teresa C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643549/
https://www.ncbi.nlm.nih.gov/pubmed/32769201
http://dx.doi.org/10.1212/NXI.0000000000000868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643549/
https://www.ncbi.nlm.nih.gov/pubmed/32769201
http://dx.doi.org/10.1212/NXI.0000000000000868

Ejemplares similares